Gyre Therapeutics, Inc. (GYRE)
After hours:
| Previous close | 11.93 |
| Open | 11.89 |
| Bid | 12.52 x 100 |
| Ask | 0.00 x 0 |
| Day's range | 11.69 - 12.88 |
| 52-week range | 4.80 - 30.40 |
| Volume | |
| Avg. volume | 77,970 |
| Market cap | 1.03B |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.03 |
| Earnings date | 12 Aug 2024 - 16 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
Simply Wall St.Estimating The Intrinsic Value Of Gyre Therapeutics, Inc. (NASDAQ:GYRE)
Key Insights Gyre Therapeutics' estimated fair value is US$7.86 based on 2 Stage Free Cash Flow to Equity Gyre...
GlobeNewswireGyre Therapeutics Announces Publication in Journal of Gastroenterology and Hepatology
SAN DIEGO, June 18, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced the publication of the manuscript titled “Hydronidone induces apoptosis in activated hepatic stellate cells through endoplasmic reticulum stress-associated mitochondrial apoptotic pathway” in the Journal of Gastroenterology and Hepatology. This publication inc
- GlobeNewswire
Gyre Pharmaceuticals Receives IND Approval from China’s NMPA to Evaluate F230 for the Treatment of Pulmonary Arterial Hypertension
SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), a clinical-stage, self-sustainable biotechnology company developing anti-fibrotic therapeutics for a variety of chronic organ diseases, today announced that the Center for Drug Evaluation (“CDE”) of China’s National Medical Products Administration (“NMPA”) has approved Gyre Pharmaceuticals’ (Gyre’s indirectly controlled subsidiary) Investigational New Drug (“IND”) application for F230 tablets, a selective endo
